First-in-Human Trial Begins for an Antisense Oligonucleotide in KCNT1-Related Epilepsy

19 Oct 2026 0 comments

A phase 1b/2 trial is testing an intrathecal antisense oligonucleotide designed to lower KCNT1 expression in children with a severe, drug-resistant epilepsy syndrome.

Source: NeurologyLive Published 19 Oct 2026 Imported 19 Oct 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment